ArticleFrontiers in immunology2025
Life's Crucial 9 and psoriasis: a mediation analysis of systemic inflammation response index using NHANES cohort data.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association between Life's Crucial 9 and psoriatic arthritis in U.S. adults: a cross-sectional study.Frontiers in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Psoriasis is a chronic, recurrent, inflammatory disease. The aim of this study was to investigate the association between the Life's Crucial 9 (LC9) score and the risk of psoriasis and to examine the mediating role of system inflammation response index (SIRI). Methods: Utilizing data from the National Health and Nutrition Examination Survey (NHANES) spanning 2009 to 2014, this study employed multifactor logistic regression, restricted triple spline analysis, and various subgroup analyses to evaluate the correlation between LC9 scores and the occurrence of psoriasis. Furthermore, mediation analyses were executed to investigate SIRI's possible intermediary effect in the linkage between LC9 scores and psoriasis. Results: This study included 11,499 US adults with 345 psoriasis patients. In fully adjusted models, a notable inverse relationship was identified between the LC9 score and the prevalence of psoriasis (OR = 0.90, 95% CI: 0.80, 0.99). After adjusting for all covariates, no significant interactions were found in the subgroup analyses. In addition, mediation analysis showed that SIRI mediated the association between LC9 and psoriasis (mediation ratio: 7.02%, p = 0.004). Conclusions: Higher LC9 scores reduce the risk of psoriasis. And, this association was mediated by SIRI. This suggests that we should actively regulate our lifestyles to improve cardiovascular health, thereby preventing and delaying the onset of psoriasis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.